Abstract-Goal: The purpose of this paper was to evaluate a nitinol tine fixation design for a transcatheter pacemaker in order to determine if the tines could be easily deployed and safely removed from the myocardium, enable low, stable pacing thresholds, and minimize the potential for dislodgment. Methods: The penetration properties of 13 human hearts were compared to the deployment and fixation energy of the tines to determine if the tines could be easily deployed and removed from the myocardium. The safety factor for dislodgement was calculated by comparing the kinetic energy of the device to the fixation energy of the tines. The fixation stability was tested in 113 chronic implants across 89 animals via pacing threshold measurements or evidence of dislodgement at necropsy. Results: Based on the tine fixation and tissue energy analysis, the tines can easily penetrate the heart. The tines can be safely removed from the myocardium based on the increased tine surface area during retraction. There were no dislodgements observed in the animals and the mean pacing threshold at implant was 0.59 +/− 0.21 V and at termination was 0.65 +/− 0.36 V. The safety factor for dislodgement was determined to be 15X during simulated exercise conditions. Conclusion: The nitinol tine fixation design enabled the implant of a self-contained pacemaker within the right ventricle and was effective in meeting the design requirements. Significance: This fixation technology provides a novel solution to enable the attachment of a transcatheter pacemaker directly within the heart.
I. INTRODUCTION
T RANSCATHETER pacemakers (or leadless pacemakers) offer several advantages over traditional leaded systems, including: elimination of the subcutaneous pocket and pocket related complications (i.e., pocket infection, pocket hematoma) and elimination of lead-related complications (i.e., lead fracture, lead dislodgement). Because of these potential benefits, we have developed the Micra TM Transcatheter Pacing System (TPS, not available for sale, currently under clinical investigation), which is a self-contained, full featured VVIR pacemaker that is designed to be percutaneously delivered to the right ventricle (RV) via the femoral vein [1] . As such, the pacemaker is 0.8 cc, 1.76 g, 25.9-mm long, and 6.7 mm in diameter. Although the idea of a self-contained intracardiac pacemaker has existed This paper has supplementary downloadable material available at http:// ieeexplore.ieee.org (File size: 23 MB).
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Fig. 1. TPS fixation procedure:
The delivery system is navigated to the RV and tip pressure applied to the myocardium via the delivery system (a). The device cup is retracted and the tines begin to tent, and subsequently, penetrate the myocardium (b). Tines are partially deployed in the myocardium as the cup is further retracted (c). Tines are fully deployed in the myocardium and the device cup is completely retracted, leaving the tether attached to the device (d).
since the 1970s [2] , the miniaturization and fixation technology has only recently become available to make this concept a reality.
One new challenge for this transcatheter pacing system was the development of a novel fixation mechanism needed to attach the pacing capsule to the heart. The fixation mechanism that we developed (FlexFix TM Tines) for this device consists of four, self-expanding, nitinol tines (see Fig. 1 ). Furthermore, these tines were designed to fulfill the following four basic requirements:
1) tines must be easily deployable into the myocardium; 2) tines must be easily removed with minimal damage to the myocardium, in order to facilitate device repositioning, retrieval and extraction; 3) tines must hold the electrode in stable contact with the myocardium in order to maintain low, stable pacing thresholds; 4) tines must minimize the potential for dislodgement.
II. FIXATION MECHANISM DESCRIPTION
The fixation mechanism for the Micra consists of four self-expanding nitinol tines that are loaded in the device cup on the distal end delivery catheter prior to implant [see Fig. 1 (a) ]. During the implant procedure, the catheter is navigated to the RV, tip pressure is applied [see Fig. 1 (a) ], and the device cup is manually retracted via a sliding button [see Fig. 1 
(b)-(d)]
causing the tines to self-expand into the myocardium. More specifically, when the device cup is retracted, the release of 0018-9294 © 2015 IEEE. Translations and content mining are permitted for academic research only. Personal use is also permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications standards/publications/rights/index.html for more information. Fig. 2 . Illustration of the straight section of the tine-tissue interface during initial penetration of the endocardial surface. A force is applied to the tine tip, which displaces the tissue (tenting) and generates pressure (a and b). As the tine moves forward and the tissue continues to displace, the pressure increases to the point at which the tine penetrates the tissue (c). Once the tissue is penetrated, the pressure is relieved and the tissue returns to its native position (d).
the spring energy stored in the tines in combination with the applied tip pressure results in forward pressure causing the tines to initially penetrate the endocardium, and subsequently, push through the myocardium to return very close to their original shape. In the deployed state, the tines are designed to hold the steroid eluting electrode (2.5-mm 2 CapSure Sense, positioned in the center of the distal end of the pacing capsule) in close contact with the myocardium in order to maintain low, stable pacing thresholds, and to minimize the risk of dislodgement. The CapSure sense is a steroid eluting (Dexamethasone acetate), Platinum/Iridium electrode with a porous Titanium Nitride coating and a 2.5-mm 2 surface area.
III. METHODS

A. Tissue Penetration Testing
In order for a tine to penetrate the myocardium (requirement #1), not only does the tine have to exert a force greater than the peak force required to penetrate the tissue, but the tine must also displace the tissue a given distance in order to generate this required peak force. In other words, the tine must "tent" the tissue prior to penetration, as further illustrated in Fig. 2 , which illustrates the straight section of the tine-tissue interface during initial penetration of the endocardial surface. Therefore, the penetration requirement was approached as an energy requirement, defined by maximum force and maximum displacement. With respect to tine penetration, the goal was to maximize the ability of the tines to penetrate the endocardial surface during implant to assure fixation, and to minimize penetration of the epicardial surface, in order to minimize tine perforation into the pericardial space. Therefore, the penetration properties of both the endocardial surface and epicardial surface of human hearts were tested.
In order to determine the required energy needed to safely penetrate the human ventricular myocardium, the tissue penetration properties of the RV were characterized in 13 fresh human hearts, which were obtained within 24 h of cross-clamp time and stored using cold preservation via a donor network (The International Institute for the Advancement of Medicine, Edison, NJ, USA) after Institutional Review Board approval and informed consent. The median age of the donor hearts were 66 years, with a range of 56-76 years. In addition, five of the donor hearts had a history of cardiac disease reported: 1) valve regurgitation, 2) heart murmur, 3) aortic valve replacement and atrial fibrillation with heart failure, 4) coronary artery disease and myocardial infarction with multiple stents, and 5) chronic heart failure with hypertension. The penetration characteristics of the endocardial surface were tested by moving a penetrator (having the substantially equivalent effective surface area of the tine tip) with a constant speed of 120 mm/min, in a quasi-static fashion, toward the endocardium of the tissue sample from within the RV until the sample was penetrated. The speed of the penetration testing was chosen to be quasi-static in order to ensure consistent results without dynamic effects [3] . The penetration properties of the epicardial surface were tested in the same manner, except the penetrator was moved toward the epicardium of the tissue sample, from the outside surface of the heart. The epicardial surface penetrations were tested from the outside surface of the heart in order to isolate the epicardial tissue properties from any boundary effects, as an artificial backing material had to be used underneath in order to physically support the sample. The tissue samples were tested at room temperature and kept moist with saline. Although the tine also has a curved section in the design, a straight penetrator was used to penetrate the tissue for the benchtop test. This was done to simulate the straight section of the tine that interfaces with tissue upon initial penetration, and also served to isolate the tissue properties; the flexible curved area of the tine design serves to store the energy required to cause the straight section to penetrate the endocardium upon deployment.
A total of 286 endocardial penetrations and 275 epicardial penetrations were randomly distributed in the apical, septal, outflow tract, and freewall regions of the RV. The force and displacement of the penetrator were continuously recorded for the duration of the test. After the data were collected, the forcedisplacement curve was integrated for each test in order to determine the total energy required to penetrate the tissue.
In order to determine if the tine could safely be removed from the myocardium without damaging tissue after implant (requirement #2), the penetration properties of the heart with a much larger surface area penetrator must be known. Although the system is designed to provide countertraction via the device cup when repositioning and removing the pacing capsule, we wanted to ensure that pulling out the tines without countertraction would not cause trauma to the tissue. When pulling out the tine without countertraction, approximately half of the inside flat area of the tine resists the retraction force, which is approximately 26 times more surface area than the tip of the tine penetrating tissue during initial deployment as illustrated in Fig. 3 . Therefore, the relationship between penetration energy and surface area was determined using similar recording of force and displacement at 120 mm/min with various penetrator surface areas, except using a man-made tissue replicator (The Chamberlain Group, Great Barrington, MA, USA). The tissue penetration energy at a surface area equivalent to the inside surface area of the tine (see Fig. 3 ) was compared to the holding energy of the tines upon retraction to determine if the tines would damage tissue upon retraction. In other words, it was assumed that if the tine holding energy was less than the energy required to penetrate the tissue with the equivalent surface area of the inside of the tine (see Fig. 3 ), the tissue would not be penetrated or damaged when the tines are retracted from the heart simply by pulling the device out of the myocardium via the tether; rather the tines would flex and unfold rather than tear tissue.
B. Tine Energy Characterization
In order to determine if the tines could safely penetrate the myocardium during implant, and minimize dislodgment due to in vivo heart motion, it was necessary to characterize the spring energy of the tines during the implant procedure (deployment penetration energy), and after deployment (tine holding energy or retraction energy). The holding and deployment energy characteristics of the nitinol tines were determined by retracting and deploying the TPS through the delivery catheter in a full cycle test at room temperature at a constant speed of 120 mm/min, while continuously measuring force and displacement. The force-displacement curves were integrated to determine the deployment energy of the tines, and holding energy of the tines (retraction test), using a total of 95 samples. Since each TPS sample contained a total of four tines, the energy results for a single tine were obtained by dividing the energy results by four. As such, the tine energy during deployment and retraction was compared to the penetration energy results from the tissue testing in order to determine if the tines could safely penetrate and be removed from the myocardium (requirements #1 and #2). Also, the tine holding energy was compared to the measured in vivo kinetic energy of the device to determine the safety factor for dislodgement (requirement #4).
C. Chronic Animal Study and Determination of the Safety Factor for Dislodgment
This is a metaanalysis of a group of animal studies that were performed to characterize various aspects of the TPS including; safety, pacing performance, rate response, and tine reliability. For this study, only the data pertaining to the fixation stability and device acceleration (used to calculate the safety factor for dislodgement) are reported.
A total of 113 devices with tine fixation were implanted in 89 animals, consisting of 20 Micro Yucatan swine and 69 sheep, with median implant duration of 12 weeks (range 6-91 weeks). The devices were implanted in both the right ventricular apex (RVA, n = 77 devices) and right ventricular outflow tract (RVOT, n = 36 devices) positions via a jugular approach and the number of tines engaged in tissue was determined by doing a "pull and hold" test under fluoroscopy. Pulling on a tether (placed through the lumens of the delivery catheter) that was attached to the device created tension on tines that would deflect the tines that were embedded in the tissue and this deflection could be seen on a fluoroscopic cine (see Fig. 4 ). Tines not engaged in the tissue would not deflect during the test. The devices were repositioned if fewer than two tines were engaged in the tissue. Retracting the tines back into the delivery cup for repositioning did not cause any permanent deformation of the tines. The live deployment of the pacemaker in the swine RV can be seen Online Supplemental Video 1. Pacing thresholds (at 0.2-0.27 ms) were measured in 67 devices (10 swine, 57 sheep) that were electrically active, where the remaining 46 devices were mechanical emulators. The stability of the fixation mechanism was determined by analyzing the chronic pacing threshold changes, and any evidence of dislodgement (requirements #3 and #4). More specifically, changes in the chronic pacing threshold were determined by subtracting the threshold at implant from the final threshold at termination. The pacing threshold was used as the electrical parameter to determine electrode stability because the pacing threshold nonlinearly increases as the electrode is separated from viable tissue within a range of millimeters. In contrast, the sensed R-wave is more sensitive to electrode spacing and angle to the depolarizing wave front and depends mainly on the viability of approximately 1 or 2 cm 3 of myocardium immediately under the tip electrode [4] - [5] . Device dislodgment was determined by analyzing the pacing threshold trend, fluoroscopy images at implant and termination, and by gross necropsy. In a subset of ten Micro Yucatan swine, cardiac tissue around the Micra was fixed in formalin, sectioned, and stained with Masson's Trichrome to characterize the fibrotic tissue surrounding the tine tracts. These studies were approved by an Institutional Animal Care and Use Committee at the Medtronic facility, and every aspect of this study conformed to the Guide for the Care and Use of Laboratory Animals.
In order to determine the safety factor for dislodgment, the holding energy for a single tine, and two tines was compared to the calculated in vivo kinetic energy (KE) of the device (requirement #4). First, the acceleration of the device was determined by placing a three-axis accelerometer in a TPS mechanical emulator and recording the peak-to-peak endocardial acceleration in an awake sheep at rest, and in an anesthetized sheep during a dobutamine challenge (12-μg/kg/min infusion). The peak acceleration data used for the rest condition were the maximum acceleration observed from a total of four awake sheep in the study, and the dobutamine challenge data were the maximum observed from a single anesthetized sheep. Next, the KE was calculated by integrating the acceleration versus time trend during the largest acceleration impulse to derive the velocity and by using the formula
It was assumed that the acceleration of the device was a good estimate of the endocardial acceleration. Therefore, for the device energy calculation, the maximum acceleration trace of the three-axis accelerometer was used as a worst-case endocardial acceleration use condition. In other words, it was assumed that potential device implants could be oriented such that this maximum acceleration would act along the long axis of the device, opposing the tine holding forces.
IV. RESULTS
A. Tissue Penetration Testing
An example of the force-displacement relationship for a single tine penetration of the endocardial surface is shown in It was found that the mean energy, peak force, and peak displacement required to penetrate the heart from the epicardial surface was greater than the energy required to penetrate the endocardial surface. More specifically, the mean energy required to penetrate the epicardial surface (with 95% confidence intervals for the mean) was 2.99 E-03 J (2.35 E-03, 3 .49 E-03), or approximately four times the mean energy required to penetrate the endocardial surface 7.98 E-04 J (5.44 E-04, 1.05 E-03). The mean peak force required to penetrate the epicardial surface was 2.8 times greater than the mean peak force required to penetrate the endocardial surface.
B. Tine Energy Characterization
An example graph of a tine retraction test is shown in Fig. 6 . The graph shows the normalized retraction force versus the displacement of the tester, where the shaded area represents the region that was integrated to determine the retraction energy. The retraction energy for this example test was 2.54 E-03 for a single tine. Overall, the mean retraction energy for a single tine (with standard deviation) was 2.919E-03 +/− 2.822E-04 J for all 95 samples.
An example graph of a tine deployment test is shown in Fig. 7 . The graph shows the normalized deployment force versus the displacement of the tester, where the shaded area represents the region that was integrated to determine the deployment energy. The deployment energy for this example test was 7.44E-04 for a single tine. Overall, the mean deployment energy for a single tine (with standard deviation) was 9.722E-04 +/− 1.369E-04 J for all 95 samples. The deployment energy was less than the retraction energy due to the superelastic hysteresis in the nitinol material, which reduces the energy storage efficiency [6] . This also resulted in the deployment and retraction curves having different peaks and valleys.
When evaluating the effectiveness of the tine to penetrate the endocardial surface to ensure fixation, it should be noted that the mean tested energy during deployment (9.722E-04) was greater than the mean tested energy required to penetrate the endocardial surface (7.98 E-04 J). Therefore, on average, the tines will effectively penetrate the myocardium for proper fixation. Also, the mean deployment energy was less than the energy required to penetrate the epicardial surface (2.99 E-03 J), which reduces the potential risk of tine perforation of the epicardial surface. However, it should be noted that risk of epicardial perforation of the tines will depend on many factors (i.e., wall thickness, trabeculation within the heart, implant position) and this potential risk could not be determined in this study.
When multiple penetrators varying in surface area were tested using a silicone tissue replicator, it was found that the penetration energy (Joules) linearly increased (R 2 = 0.99) with respect to surface area (mm 2 ) of the penetrator, where Penetration Energy = 0.0063 * surface area + 0.0004.
Based on this linear relationship, and a 26 times surface area difference between the tip of the tine interacting with tissue during deployment, and the tine area interacting with tissue during retraction, it would require a minimum of 26 times the energy to penetrate/tear the tissue during retraction than deployment. Therefore, there is an approximate safety factor of 26X with respect to tearing tissue when pulling out the tines without using the cup for counter traction. A video showing the tines pulled from the right ventricular myocardium of a human donor heart is shown in Online Supplemental Video 2.
C. Chronic Animal Study and Determination of the Safety Factor for Dislodgment
No dislodgements were observed in any of the 113 transcatheter pacemakers implanted, as confirmed by gross necropsy and fluoro image analysis. The median number of tines engaged in tissue at implant was 2 (min = 1, max = 4). In addition, the mean pacing threshold at implant was 0.59 +/-0.21 V and at termination was 0.65 +/-0.36 V. A summary of the chronic mean pacing threshold trend and pacing threshold changes are shown in Figs. 8 and 9 , respectively. As shown in the histogram, only five animals had pacing threshold increases >0.5 V, and only one animal had a pacing threshold increase >1 V. Overall, the pacing thresholds were low and stable. The average maximal thickness of fibrotic tissue around the tine tracts was 1.06 +/-0.41 mm. An example histology image is shown in Fig. 10 . The relatively small amount of tissue measured surrounding the tines, and the low and stable chronic pacing thresholds indicate that the fixation mechanism and the electrode tissue interface are stable. Also, the fixation mechanism is separated from the electrode such that the fibrotic tissue surrounding the tines does not interfere with the ability of the electrode to pace viable tissue.
Sample traces from the raw accelerometer signals during rest are shown in Fig. 11 . It was found that the maximum peak to peak acceleration was 5.41 g at rest, and a maximum of 9.15 g during a 12-μg/kg/min dobutamine infusion, where the impulse times during these peak contractions were 0.0121 and 0.0123 ms, respectively. These acceleration values and impulse times were subsequently used to calculate the device velocity, and resulting device KE, where the device KE was 6.50 E-05 J at rest and 3.34 E-04 J during the dobutamine challenge. The safety factor for dislodgment was calculated as the tine holding energy divided by the device kinetic energy, where 2.55 E-03 J was used as the holding energy of a single tine, which was the minimum design specification derived from the distribution of the tine retraction test data. Overall, the estimate for the safety factor was relatively high, as for a single tine engaged in tissue, there is an estimated 39X safety factor for dislodgement at rest and a 8X safety factor during simulated exercise conditions (dobutamine challenge). For two tines engaged in tissue, which would provide twice the holding energy, there is an estimated 79X safety factor for dislodgement at rest, and a 15X safety factor during exercise conditions. Although there is a high margin of safety for dislodgment based on these analyses, two tines are required to engage the tissue at implant for fixation redundancy.
V. DISCUSSION
Transvenous pacing leads implanted endocardially in the RA and RV have traditionally used two basic types of fixation mechanisms, either passive fixation polymer tines or active fixation helixes [7] . Although both types of fixation mechanisms have been successfully implemented in pacing lead designs across multiple manufacturers, it was unclear whether these designs could be upsized to accommodate a 20 French transcatheter pacemaker design and meet the necessary pacing, fixation, and safety requirements. Also, it must be considered that there is a reported 0.7% [8] to 5.6% [9] rate of lead dislodgment, with the majority occurring acutely [10] . Although the mechanisms of lead dislodgement cannot always be identified, some dislodgements occur due to tension applied by the lead body on the pacing electrode when the lead is not properly anchored. On the contrary, the lead body can also aid in fixation via constant light pressure, which can ensure the electrode is held against viable tissue. In contrast with pacing leads, the transcatheter pacemaker has no lead body, and the entire device mass (1.76 g) moves with the heart wall, thereby creating a new set of use conditions for this TPS technology. Because of these differences in loading conditions, and the spring type behavior of the tines during deployment and retrieval, the mechanics of the fixation mechanism could not be analyzed in the same manner as current pacing leads. It should be noted that some promising early results have been reported with a leadless pacemaker containing a helix-type fixation in 33 patients [11] with a different length/diameter profile than the Micra; however it is too early to elucidate any meaningful comparisons to the tine fixation technology with such early data.
In addition, traditional RA and RV pacing leads pace very close to the site of fixation, i.e., for an active fixation lead, the pacing electrode (helix) also serves as the fixation mechanism in most cases. As such, the implantation of active fixation leads is associated with a current of injury, where the pacing threshold is initially higher immediately after implant due to acute local insult to the tissue and is significantly reduced over time [12] , [13] . In order to sufficiently separate the fixation mechanism from the pacing electrode to maintain low, stable thresholds and minimize dislodgment for dynamic use conditions, active fixation nitinol tines were used for this design. Due to its quite novel nature, the tine design was evaluated via preclinical bench-top and in vivo animal studies in this study in order to demonstrate: 1) the tines are easily deployable into the myocardium, 2) tines are easily removed without damaging the myocardium, 3) tines hold the electrode in stable contact with the myocardium maintaining low, stable pacing thresholds, and 4) tines minimize the potential for dislodgement. Based on the preliminary results presented here, the tine design can sufficiently penetrate the endocardial surface of the human heart in order to assure adequate fixation. And, once the tines are engaged in tissue, the electrode tissue interface and pacing thresholds are stable and there is a low probability of device dislodgment. Minimizing the risk of dislodgement becomes increasingly important as a dislodged transcatheter pacemaker could potentially be mobile (causing embolization) and more difficult to recapture in comparison to a pacing lead, which is typically anchored subcutaneously within a suturing sleeve. Also, in the event that the device needs to be acutely repositioned or chronically extracted, the tines will deflect and pull out of the tissue while minimizing tearing of the myocardium.
Although the use of animals and bench-top testing was thoroughly utilized in this study, the true safety profile of the tine design must be evaluated in a clinical study, and some limitations are noted. One limitation in assessing the safety factor for dislodgment for rest and exercise conditions was that it was difficult to obtain human data in the format needed to do such calculations (i.e., acceleration versus time traces). In previously published work, peak endocardial acceleration was investigated in humans as a method to use for rate response in pacing systems [14] - [18] . While these data were published, the digital signal was not available for integration, the leads only had a single axis accelerometer, and the endocardial acceleration measured via the sensor in the lead may not represent the acceleration of the endocardium with an implanted TPS. Therefore, the time versus acceleration signals that were collected in sheep using a threeaxis accelerometer were used to determine the dislodgement safety factor for rest and exercise conditions. As a comparison, the published endocardial acceleration values range from ∼0.24 to 1.1 g at rest and ∼0.65 to 3.7 g during exercise [14] - [18] . From the data collected in sheep, the maximum peak-to-peak acceleration was 9.15 g during a 12-μg/kg/min dobutamine infusion, and a maximum of 5.41 g at rest. Noting the limitations to the published data discussed previously, the data used from the sheep measurements in this study would yield a conservative estimate of the dislodgement safety factor in humans.
Another limitation in this study was the availability of fresh human hearts available for study. Here, 13 fresh human hearts, obtained within 24 h of cross-clamp time and stored using cold preservation were used to characterize the penetration characteristics of the human heart to aid in designing the fixation mechanism. With 13 hearts tested, it was difficult to obtain and test any outliers. For example, pericardial effusion, a sign of cardiac perforation, occurs at a rate of approximately 1.2% with traditional pacing leads, where the strongest predictor for pericardial effusion was the use of oral steroids [19] . Weaker predictors included right ventricular systolic pressure, use of helical screw ventricular leads, body mass index <20, and older age [19] . This implies that the tissue properties of the myocardium can be quite variable and patient specific. With the hearts that were collected here, we focused on testing hearts that would represent the appropriate age of pacemaker patients, but could not elucidate variables that may weaken the heart wall such as chronic oral steroids. Also, because of this variability in tissue properties, the tines may not always penetrate the myocardium using only the spring energy stored in the tines. If a situation is encountered where the tines do not penetrate the myocardium (i.e., if the tine encounters scar tissue), tip pressure can be applied to aid in penetration of the tines, which will result in an increase in deployment energy (and force).
The mean pacing thresholds in this study were low and stable, with a maximum increase of 1.38 V observed for one sheep as shown in the histogram (see Fig. 9 ). For this animal, the final measured pacing threshold was 1.88 V at 0.24 ms at 91 weeks, which would still allow an adequate safety margin relative to the maximum output of the device (5 V). This single animal also skewed the pacing threshold trend beginning at 38 weeks as shown in Fig. 8 , as only three animals were followed between weeks 38-91. No unusual observations at the implant site were observed for this animal. In addition, although there were no dislodgments observed in any of the 113 implants, it should be noted that the human heart is highly trabeculated in comparison with sheep and pig hearts [20] . It is unclear if the dislodgement rate will be similar in the human heart, although the initial experience in man for the first 140 patients implanted with the Micra TPS demonstrated good fixation, and low, stable pacing thresholds with no dislodgements [21] .
More specifically, for 60 of these patients that were followed for at least three months, the mean pacing capture threshold decreased from 0.57+/-0.31 V at implant to 0.51+/-0.22 V at three months with no increase in threshold between these two time points [21] . The collection of devices shown in this study comprises a variety of tine designs from quite stiff to quite soft. The changes in threshold over time for some of the animals were mostly found in the early devices with the softest tines.
For simplification, the tests developed in this study assumed the delivery cup would be perpendicular to the surface of the heart during tine deployment. However, the design is not limited to such situations. As shown in Fig. 1(b) , the tines are deployed at an angle as the cup is retracted: therefore, as long as the end of the device cup is surrounded by tissue (i.e., the RVA location within the heart) or perpendicular to tissue, the tines will penetrate. Also, the delivery catheter is deflectable and can be oriented such that the tip of the catheter can be perpendicular to multiple implant locations within the heart such as RVOT and septal positions. Accordingly, the heart walls are flexible, and applying tip pressure to the heart wall prior to deployment will allow some conformation of the myocardium around the tip of the catheter. Also, in the trabeculated human heart, it is possible that the tines could engage trabeculae surrounding the device, also aiding in fixation. The RVA and RVOT placements in the animal hearts have shown some of the implant flexibility in this regard.
Because of the variation in the placement of the Micra within the heart, the exposure of the tips of the tines within the blood pool after deployment will be variable based on implant location; for example, in the RVOT, the deployment is more similar to the case in Fig. 3 where the device is deployed against a flat surface and the tine tips are exposed. In the apex, which is more shaped like a cone, the tines will penetrate at an angle to the heart wall, and can be completely embedded in the myocardium as shown in Fig. 10 . Both of these scenarios were tested in vivo, and the percentage of tine exposure within the blood pool did not affect any of the measured performance metrics as outlined in this paper.
In this study, the thickness of the RV wall was not measured, as the tissue penetration properties of the endocardium and epicardium were used to design the tines to ensure penetration of the endocardial surface for good fixation, and to minimize perforation of the epicardial surface. In other words, the penetration of the heart by the tines is not displacement controlled, but bounded by the energy differences between the layers of the heart. If a scenario is encountered where the deployment energy is higher than the energy required penetrate the epicardial surface (for epicardial penetration energies at the lower outlying tail of the distribution), the thickness of the heart wall relative to the tine length will have an impact on the probability that a tine may penetrate the epicardial surface. However, these situations could not be evaluated using the simplified bench-top testing methods and relatively small human heart sample size in this study.
Other limitations of the bench-top testing were: 1) the effects of the contraction of the heart wall against the catheter/tine tip with respect to the penetration energy could not be determined, 2) the tests could not account for varying angles between the tine tip and the heart wall, 3) the tests were conducted at room temperature rather than at body temperature, and 4) the benchtop tests were run in a quasi-static fashion because the speed of the deployment could vary based on implanter technique and experience. Because of these limitations, the functionality of the tine design was also tested in vivo. Although the bench-top testing carried multiple assumptions and limitations, the in vivo animal testing and the early results of the human clinical trial show promise that the methods used in this study were sufficient to fulfill the design requirement goals Although the tines have been designed to be flexible in order to facilitate removal, it is unclear how easily the device can be chronically extracted. However, it is also unclear of the necessity for chronic extraction of the device with only early human data, where no retrievals or extractions were necessary [21] . Early extraction work in sheep has shown the device can be safely removed after 18 months [22] . Only after these types of pacemakers become more widely utilized, can the true need for extraction for such a small device be elucidated.
VI. CONCLUSION
Overall, based on preclinical work and early reports in man using this technology, this novel fixation mechanism is promising to provide a safe and effective method to attach the TPS to the right ventricular myocardium. Based on penetration testing of human hearts and energy analysis of the fixation mechanism, the tines are easily deployable into the myocardium, and can be easily removed without damaging the myocardium. In addition, the fixation provides low stable chronic thresholds and no dislodgements have been observed in 113 implants across 89 animals, with a high estimated safety margin for dislodgement based on endocardial acceleration. The long-term performance of this fixation mechanism in humans will need to be studied in order to confirm the preclinical results reported here. Although not evaluated here, the fixation technology could be applied to other devices attached within the RV such as pressure sensors or other monitoring devices.
